Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc. has demonstrated promising results with its product candidate KSI-101, showing significant vision improvements and high rates of retinal dryness in a substantial majority of patients by Week 8. The company's tarcocimab has also achieved all secondary endpoints in clinical trials, evidencing a notable reduction in sight-threatening complications, thereby supporting confidence in its potential market impact. Together with progressive advancements in its pipeline and positive feedback from retinal key opinion leaders (KOLs), these factors contribute to a favorable outlook for Kodiak Sciences' stock.

Bears say

Kodiak Sciences Inc has encountered significant challenges with its product candidates, specifically marked by multiple trial failures, including the Phase 3 GLEAM and GLIMMER trials in DME and the Phase 2b/3 DAZZLE trial in wet AMD. The company reported a notable net loss of $61.5 million, equating to $1.16 per diluted share for the third quarter of 2025, raising concerns over its financial health. Additionally, substantial risks are associated with the company's ability to secure necessary capital and achieve expected commercial revenue from its pipeline products, further supporting a negative outlook.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.